7 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
lowered CV events in T2DM ... lowered CV events in T2DM ... + T2DM; first renal ... with or without T2DM ... visualabstract #table
A1C and eAG
~
*For Educational Purposes Only*

#Diabetes #T2D #DM2 #Table #PrimaryCare #Endocrinology #BloodGlucose #A1C
#Diabetes #T2D ... #DM2 #Table #PrimaryCare
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
Patients With CKD ... patients with T2D ... , CKD, & an eGFR ... ml/min per 1.73 m2 ... #Diabetes #CKD #
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Ozempic), or daily tablet ... patients with T2D ... Pharmacology #Summary #DM2
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Sulfonylurea, TZD ... insulin by ~20% • Never ... Diabetes #Mellitus #DM2 ... pharmacology #comparison #table
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
or family - Ever ... metabolic equivalent able ... Insulin dependent DM ... event, follow ACC algorithm ... Stable patients
Hyperkalemia - Diagnosis and Management - GrepMed Handbook

S/Sx: Most pts asymptomatic. Weakness, cramping, nausea, paresthesias, palpitations,
transfusions), ↓insulin (DM ... VBG (acidosis), CK ... Elimination (see Table ... Na-Zirconium (10g PO tid